Case Report

Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod

Tim Sinnecker,1,2,3 Jalal Othman,1 Marc Kühl,1 Imke Metz,4 Thoralf Niendorf,5,6 Annett Kunkel,1 Friedemann Paul,2,6,7,8 Jens Wuerfel,2,9 and Juergen Faiss1

1Department of Neurology, Asklepios Fachklinikum Teupitz, Teupitz, Germany
2NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany
3Department of Neurology, Universitätsspital Basel, Basel, Switzerland
4Department of Neuropathology, Universitätmedizin Göttingen, Göttingen, Germany
5Berlin Ultrahigh Field Facility, Max Delbrück Center for Molecular Medicine, Berlin, Germany
6Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany
7Clinical and Experimental Multiple Sclerosis Research Center, Charité-Universitatsmedizin Berlin, Berlin, Germany
8Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany
9Medical Imaging Analysis Center AG, Basel, Switzerland

Correspondence should be addressed to Friedemann Paul; friedemann.paul@charite.de

Received 1 June 2016; Revised 21 August 2016; Accepted 12 October 2016

1. Introduction

Progressive multifocal leukoencephalopathy (PML) is an opportunistic infection of the central nervous system (CNS) caused by JC polyomavirus (JCV) targeting oligodendrocytes and astrocytes and leading to oligodendrocyte death [1]. Symptoms are greatly variable, depending on the localisation of the infection in the brain [2]. Clinically, patients present with behavioural abnormalities, cognitive impairment, focal neurological deficits, and/or epileptic seizures. The course of the disease is often fatal or rendering the patient severely disabled [2].

PML is observed in patients with a marked immunosuppression, for instance, due to an infection with HIV or as a result of an immunosuppressive therapy after organ transplantation. It may also occur in multiple sclerosis (MS) patients treated with natalizumab (NTZ). NTZ is a monoclonal antibody directed against α4-integrin that hinders the transmigration of white blood cells through the blood vessel wall into the CNS. Risk factors of NTZ-associated PML are duration of therapy with NTZ (with a marked increase in risk after two years), use of immunosuppressants before initiation of NTZ therapy, and a positive anti-JC virus antibody status [3–7].
**Timeline**

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jan 15</td>
<td>Discontinuation of NTZ</td>
</tr>
<tr>
<td>Mar</td>
<td>Discontinuation of fingolimod and plasma exchange (5 cycles)</td>
</tr>
<tr>
<td>Apr 10/13</td>
<td>Negative PCR for JCV DNA in CSF; JCV-ASI 7.3</td>
</tr>
<tr>
<td>Apr 21, 2015</td>
<td>Negative PCR for JCV DNA in CSF; JCV-ASI 10.3</td>
</tr>
<tr>
<td>May 22, 2015</td>
<td>1094 copies of JCV DNA/10 𝜇L biopsy extract</td>
</tr>
<tr>
<td>June 11, 2015</td>
<td>Discontinuation of fingolimod; mirtazapine 30 mg/d; plasma exchange (3 cycles)</td>
</tr>
<tr>
<td>July 13, 2015</td>
<td>1.5 T T1 weighted Gadolinium enhanced (T1w GAD) and 1.5 T fluid attenuated inversion recovery (FLAIR) images are presented.</td>
</tr>
<tr>
<td>Jan 26, 2015</td>
<td>1.5 T T1 weighted Gadolinium enhanced (T1w GAD) and 1.5 T fluid attenuated inversion recovery (FLAIR) images are presented.</td>
</tr>
</tbody>
</table>

**After clinical suspicion of PML, diagnosis is established by magnetic resonance imaging (MRI) findings and PCR detection of JCV DNA in the cerebrospinal fluid (CSF) [8]. In rare cases, a brain biopsy has to be performed to diagnose PML [8].**

Apart from reestablishing a competent immune response, there is no PML-specific therapy with proven efficacy [9]. In MS patients with NTZ-associated PML, plasma exchange (PLEX) or immunoadsorption (IA) is performed to accelerate NTZ clearance [10]. However, immune reconstitution inflammatory syndrome (IRIS), a condition characterized by an overwhelming inflammatory response during immune reconstitution, can develop or deteriorate during PLEX leading to clinical worsening [11].

In vitro studies postulate an infection via the serotonin receptor 5HT2a [12]. Hence, serotonin reuptake inhibitors like mirtazapine are frequently prescribed. However, along with other experimental therapeutic strategies including mefloquine or amantadine, clinical confirmation is still missing [13].

Here, we report an MS case in which PML-IRIS was diagnosed after switching from NTZ to fingolimod. Brain biopsy and advanced neuroimaging findings including ultra-high field MRI at 7 Tesla (T) are presented.

**2. Case Presentation**

A 48-year-old woman with relapsing-remitting MS (RRMS) was switched after 6 months of treatment with interferon-1b to NTZ in May 2008 due to ongoing clinical and paraclinical disease activity including multiple Gadolinium enhancing brain lesions detected with MRI.

At that point, the Expanded Disability Status Scale Score (EDSS) was 5.5.

We did not observe any evidence of clinical or MRI disease activity during NTZ treatment, and the EDSS subsequently decreased to 2.5.

Figure 1 chronologically summarizes all paraclinical findings including MRI results and treatment decisions.

In January 2015, NTZ was discontinued after a total of 86 infusions on the background of seroconversion to positive JCV serum antibodies (STRATIFY, Unilabs, Geneva, Switzerland), indicating an increased PML risk. Anti-JCV antibody index was not available at that time.
After a wash-out period of 2 months, fingolimod was started on the 18th of March 2015. Previous brain MRI (February 2015) did not show any signs of PML.

Three weeks later (10th April 2015), routine brain MRI at 1.5 T revealed PML-suspicious bifrontal confluent lesions with (sub)cortical involvement. Moreover, multiple milky-way-like Gadolinium enhancing and T2 weighted (T2w) hyperintense punctate lesions were detected by MRI in these areas (Figure 1). In addition, perilesional contrast enhancement around confluent PML-suspicious lesions suggestive of IRIS was detectable (Figure 2). Diffusion weighted MRI did not show intraleSIONal hyperdiffusivity nor signs of restricted diffusion at the edge of the lesions (Figure 3); both of which are considered to be typical of PML [14].

We did not observe any signs of clinical worsening, the polymerase chain reaction (PCR) testing for JCV DNA in CSF (Institute for Virology, Heinrich Heine University, Düsseldorf, Germany) was negative, and the lymphocyte count was only slightly decreased (0.91 G/L, reference range 1–4 G/L).

Fingolimod was immediately discontinued, and the patient underwent five cycles of plasma exchange. Ultrahigh field MRI at 7 Tesla was performed five days after discontinuation of fingolimod confirming initial 1.5 T MRI findings by detailing confluent PML-suspicious lesions with (sub)cortical involvement (Figure 4) and by delineating numerous punctate Gadolinium enhancing lesions (Figure 5, circles) on top of MS-suspicious ring-enhancing lesions (Figure 5, white arrows).

1.5 T MRI performed immediately after PLEX did not show any signs of PML progression (Figure 1), and PCR did again not reveal JCV DNA in CSF. Thus, fingolimod was reinitiated on 22th of April 2015 to prevent possible rebound effects after discontinuation of NTZ, and monthly MRIs were performed.

One month later (22th of May 2015) a control MRI at 1.5 T showed slightly enlarging FLAIR hyperintense lesions (Figure 1). Clinically, we observed a latent right-sided brachiofacial paresis and a slightly increased irritability reported by her daughter at that time; EDSS 3.0. PCR testing for JCV DNA in CSF was repeatedly negative, but JCV antibody index (JCV-ASI) was markedly increased (10.3). Retrospectively, JCV-ASI was already elevated at the time of the second CSF analysis (JCV-ASI 7.3).

As a consequence, fingolimod was again discontinued, mirtazapine 30 mg/d orally was started, and another cycle of plasma exchange was carried out. Neuropsychological examinations and electroencephalography (EEG) did not reveal any changes.

On 24th of July 2015, a stereotactic biopsy was carried out since an ultrasensitive PCR of JCV DNA (Laboratory of Molecular Medicine and Neuroscience, National Institute of Health, Bethesda, USA) repetitively failed to detect JCV DNA in CSF. The biopsy showed demyelinating lesions with a prominent CD8 dominated inflammatory infiltrate with numerous plasma cells (Figure 6). Although neuropathological findings were highly suggestive of IRIS in the context of PML, SV40-positive cells (JCV-infected cells) could not be detected (Institute of Neuropathology, University of Göttingen, Germany). JCV multiplex quantitative real-time PCR assay (JC Multiplex qPCR) of paraffin embedded brain tissue was initiated and revealed 1094 viral copies per 10 μL extract, consistent with a variant most commonly associated with PML (Laboratory of Molecular Medicine and Neuroscience, National Institute of Health, Bethesda, USA) [14], finally proving the PML diagnosis.

Mirtazapine was continued and glatiramer acetate treatment initiated. The patient remained clinically stable, and MRI (26th of January 2016) showed decreasing PML lesions without any signs of Gadolinium enhancement (Figure 1, EDSS 3.0).

3. Discussion

We report a case of subclinical simultaneous PML-IRIS that was diagnosed after switching from NTZ to fingolimod. Initially, PML was suspected exclusively on the basis of MRI findings despite repeatedly negative (ultrasensitive) PCR testing for JCV DNA in CSF. The diagnosis was further complicated by the absence of PML-characteristic changes in diffusivity as investigated by diffusion weighted MRI. Finally, PML was confirmed via brain biopsy.

Along with other reports in the literature [15, 16], this case thus underlines the need of additional sensitive biomarkers for an earlier diagnosis of PML. In fact, PCR testing for JCV DNA in CSF is limited in sensitivity even when using ultrasensitive PCR assays that can detect up to 10 copies of JCV DNA per milliliter CSF [8, 16]. Notwithstanding these efforts, such highly sensitive assays are not broadly available, and the clinical relevance of very low measures of JCV DNA copies is still under discussion [17].

Recently, the JCV antibody index was introduced as a novel biomarker that potentially can help to better distinguish between NTZ-associated PML and non-PML MS patients [4,
Figure 3: No signs of abnormal diffusion. Diffusion weighted MRI at 1.5 T ((a) and (c)) did reveal neither signs of central hyperdiffusibility (circles) nor signs of restricted diffusion (circles) at the edge of PML lesions (black arrows, (b) and (d)). Both of which were reported to be characteristic for PML lesions.

Indeed, the JCV antibody index was markedly increased in our case and continued to rise during PML expansion. Other PML cases of elevated JCV antibody indices despite repeatedly negative PCR testing for JCV DNA in CSF have been reported [15, 16].

Furthermore, the presented case also highlights the importance of a stringent clinical and paraclinical follow-up of MS patients before and after discontinuing NTZ since PML(-IRIS) was previously described after NTZ discontinuation [18] and while switching from NTZ to another immunomodulatory therapy. As reported previously, IRIS may even occur during fingolimod-associated lymphopenia [19, 20]. Indeed, marginally decreased blood lymphocyte counts and signs of IRIS were detectable at the time of first PML-suspicious MRI lesions in our case.

In addition to this extensive laboratory and clinical workup, we performed highly resolving ultrahigh field MRI at 7 T. In general, 7 T MRI benefits from an increased signal-to-noise ratio, a high spatial resolution, and enhanced susceptibility effects. Thus, 7 T MRI has improved the detection and morphological characterization of neuroinflammatory brain lesions [21–23]. Most importantly, a small venous vessel is often detectable within the center of MS lesions by using gradient echo MR techniques at 7 T [24–28], facilitating the distinction to other CNS diseases such as neuromyelitis optica [29, 30] and Susac syndrome [31].

Recently, 7 T MRI revealed contrast-enhancing milky-way-like lesions that expanded into more typical PML lesions over time in a single case of simultaneous PML, IRIS, and an ongoing MS disease activity [32]. In contrast to MS lesions, a small central vessel was not commonly detectable within these lesions [32].

In general, the mechanisms of contrast enhancement in NTZ-associated PML are not fully understood. Contrast enhancement is a correlate of blood-brain-barrier (BBB) breakdown [11, 13, 33–35]. However, JCV-infected lymphocytes may also cross the intact BBB to infect oligodendrocytes [36, 37]. In other words, BBB breakdown is not a prerequisite of PML development. In HIV, indeed, PML is frequently characterized by little or no inflammatory signs and absence of BBB breakdown [38]. Thus, patchy areas of peripheral contrast enhancement at the edge of HIV-PML lesions are commonly considered as a sign of IRIS but not a PML imaging feature [38, 39]. Following this assumption,
Figure 4: 7 T T2* weighted imaging in PML. A 7 T T2* weighted (T2*w) image with a spatial resolution of (0.2 × 0.2) mm is shown. Please note the difference in lesion morphology between periventricular oval MS lesions that are centered on a small venous vessel (arrows) and confluent PML lesions (circle) that also involve U-fibers and subcortical areas.

Figure 5: Patterns of Gadolinium enhancement on 7 T VIBE images. A maximum intensity projection map of a 7 T T1 weighted Gadolinium enhanced volumetric interpolated brain examination ((a), VIBE) and an exemplary VIBE image (b) are displayed. PML-suspicious punctate Gadolinium enhancing lesions are clearly visible (circles). Ring-enhancing lesions (e.g., arrows) suggestive of MS lesions are delineated.

recent PML studies have interpreted any kind of contrast enhancement in or around PML lesions as a sign of IRIS [11]. However, it is not known whether this also holds true for NTZ-associated PML, where the immune response is present and thus different compared to HIV. In a recent report, no histopathological features of IRIS were present in a biopical probe of NTZ-associated PML, despite perilesional contrast enhancement on MRI. The authors concluded that, up to date, IRIS remains a histopathological diagnosis [40]. In our case, histopathology revealed prominent CD8 dominated inflammatory infiltrates with numerous plasma cells highly suggestive of IRIS, although clinical worsening, that usually accompanies IRIS, was absent.

In addition to patchy contrast enhancement at the edges of PML lesions, punctate contrast-enhancing lesions have been described [35, 41–43]. The clinical relevance of such small punctate lesion is, however, still a matter of discussion: On the one hand, milky-way-like punctate lesions were
associated with an overwhelming immunoreaction, namely, IRIS, against JCV [43]. Methylprednisolone pulse therapy would be beneficial in such a situation. On the other hand, it was hypothesized that these lesions represent areas of active JCV replication that is probably adequately recognized by the immune system [41]. In such a scenario, glucocorticoid induced immunosuppression might be harmful. In alignment with this hypothesis, we have previously described clinical worsening and increasing JCV DNA copies in CSF in a NTZ-PML case with punctate lesions during methylprednisolone pulse therapy [32].

Interestingly, there are some differences in the clinical presentation and MRI finding between the “current” PML case presented here and the previous one [32]. In detail, we observed fewer milky-way-like lesions and the expansion of confluent lesions over time was more limited in the “current” case. Of note, the “current” patient only received plasma exchange, and she was not treated with methylprednisolone. Which of all these factors has primarily influenced the overall better clinical outcome of the presented patient remains unknown, but it emphasizes the need of systematic (ultra)high field MRI studies to address these questions.

**Disclosure**

Tim Sinnecker’s current address is as follows: Department of Neurology, Universitätsspital Basel, Basel, Switzerland.

**Competing Interests**

The authors declare that they have no competing interests.

**Authors’ Contributions**

Tim Sinnecker, Jalal Othman, Marc Kühl, Jens Wuerfel, and Juergen Faiss are equally contributing first and senior authors.

**References**


